CDNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CareDx Inc (CDNA) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock lacks significant positive catalysts, and while the company has shown revenue growth, its declining net income and EPS, coupled with mixed analyst ratings and a neutral technical outlook, suggest a cautious approach. The investor should wait for clearer growth signals or resolution of uncertainties before considering an entry.
The MACD is above 0 but positively contracting, indicating weakening momentum. RSI is neutral at 45.735, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 17.637, with support at 16.685 and resistance at 18.588, suggesting limited upside potential in the short term.
The company delivered strong Q4 revenue growth of 25.19% YoY and initiated 2026 revenue guidance above Street estimates. BTIG maintains a Buy rating with a price target of $26, citing the stock's undervaluation.
Net income and EPS have significantly declined YoY, with net income dropping by -105.27% and EPS by -107.14%. Craig-Hallum downgraded the stock to Hold due to concerns about longer-term growth and uncertainties surrounding CMS resolution. Hedge funds and insiders are neutral, with no significant trading trends.
In Q4 2025, revenue increased by 25.19% YoY to $108.39M, but net income dropped to -$4.11M (-105.27% YoY), and EPS fell to -$0.08 (-107.14% YoY). Gross margin slightly decreased to 67.24% (-0.31% YoY).
Mixed analyst sentiment: BTIG raised the price target to $26 and maintains a Buy rating, citing undervaluation. However, Craig-Hallum downgraded the stock to Hold, expressing concerns about growth dependency on CMS resolution and potential overestimation of future revenue.
